Business Wire

KALRAY/NXP

Share
Strategic Investment of NXP in Kalray

Kalray (Euronext Growth Paris : ALKAL – the “Company”), a pioneer in processors for new intelligent systems, today announces a strategic investment from NXP Semiconductors N.V. (NASDAQ: NXPI) for €8 million (approximately US$9 million), to enable the companies to develop together safe, reliable and scalable solutions for autonomous driving, combining NXP Automotive solutions and Kalray MPPA® (Massively Parallel Processor Array) Intelligent Processors.

The investment will be carried out through the reserved issuance to NXP BV, a company of the NXP Group, of 503,461 ordinary shares without pre-emptive rights for the existing shareholders of the Company. Upon settlement-delivery of the new shares, the NXP Group will hold ca. 9.95% of Kalray’s share capital and voting rights. The settlement-delivery of the new shares is scheduled for April 7, 2020 and their admission to the Euronext Growth Paris multilateral trading system is scheduled for April 8, 2020.

STRATEGIC NATURE OF THE TRANSACTION

This transaction will strengthen the partnership between NXP and Kalray that has been announced one year ago at CES 2019 which is targeting the development and deployment of a L2 (Partial Driving Automation) to L5 (Full Vehicle Automation) common hardware and software platform, for a safe, reliable and scalable autonomous driving solutions.

The funds raised will be used to both finance Kalray’s resources and investments required by the implementation of the strategic partnership with NXP, and fund Kalray’s roadmap in support of Kalray’s automotive and embedded strategy.

NXP and Kalray intend to bring an integrated, scalable solution to the automotive market, including CPU processing, neural network computing, functional safety capabilities, and an optimized tool chain – together providing the necessary requirements for next-generation ADAS and automated driving systems. The partners will also respond together to business opportunities and NXP will support Kalray in term of sales, marketing, automotive expertise and global technical support.

The next generation of the NXP BlueBox autonomous driving reference platform with NXP’s S32 family of safe automotive processors and automotive grade Layerscape® processors is set to integrate Kalray’s MPPA® Intelligent Processors and provide it to both automotive customers and NXP BlueBox eco-system.

“Delivering a platform for autonomous driving, integrating the required AI and safe compute performance, requires high levels of collaboration,” said Henri Ardevol, senior vice president and general manager Automotive Processing at NXP . “Kalray’s scalable, open platform and heritage in the industry is a complement to NXP’s deep experience, dedication to safety and portfolio in the automotive space. We are very happy to combine our expertise with Kalray to help our customers deliver increasingly automated vehicles.”

“We are honored to announce NXP is now one of our strategic investors”, said Éric Baissus, CEO, Kalray . “NXP is one of the most well-established and expert company in the automotive semi-conductor industry. This investment will further strengthen the collaboration of our teams and participate to the funding of our automotive roadmap. Together, I am convinced we have a unique solution to provide to the market for reliable autonomous driving, combining performance, openness and functional safety needs.”

DETAILS OF THE TRANSACTION

Main terms and conditions of the transaction

The investment will be carried out through the reserved issuance to NXP BV, a company of the NXP Group, of 503,461 ordinary shares of the Company (the “New Shares”) without pre-emptive rights for the existing shareholders of the Company, on the basis of article L. 225-138 of the French commercial code, in accordance with the 14th resolution of the Company’s combined general shareholders’ meeting held on May 29th, 2019 and the decisions adopted by the supervisory board and management board of the Company today (the “Reserved Share Capital Increase”).

Governance

Kalray will submit to its next shareholders’ meeting a resolution to appoint Sean Pitonak, Senior Vice President, Corporate Development and M&A of NXP as member of its supervisory board.

Details of the financial transaction

The price per New Share of the Reserved Share Capital Increase will be EUR 15.89, which represents 100,9% of the volume-weighted average closing share price of Kalray over the 20 trading days preceding the price setting date and which represents 99,0% of the volume-weighted average price of the shares of the Company during the 3-trading day period prior to the date hereof.

As an indication, a shareholder with a 1% stake in the Company prior to the launch of the Reserved Share Capital Increase will now have a stake of 0.90%.

Upon settlement-delivery of the New Shares, the NXP Group will hold ca. 9.95% of Kalray’s share capital and voting rights. To the Company’s knowledge, the breakdown in share ownership before and after the Reserved Share Capital Increase is the following:

Before transaction

After transaction

 

Shareholder

% of capital / voting rights

% of capital / voting rights

CEA Investissement

6,92%

6,23%

ACE

6,55%

5,90%

Shareholders acting together

16,75%

15,08%

Financière ARBEVEL

6,55%

5,90%

Financial shareholders (>5%)

36,78%

 

33,12%

 

MBDA

2,44%

2,19%

SAFRAN Corporate Ventures

6,99%

6,29%

PENGPAI

7,84%

7,06%

ALLIANCE Ventures

5,30%

4,77%

DEFINVEST / BPI

3,41%

3,07%

NXP

--

9,95%

Corporate shareholders

25,98%

 

33,35%

 

Free float / other

37,24%

 

33,54%

Admission of New Shares

Settlement-delivery of the New Shares is scheduled for April 7th, 2020 and their admission to the Euronext Growth Paris multilateral trading system is scheduled for April 8th, 2020. The New Shares will be listed on the same line as Kalray’s existing ordinary shares, will carry dividend rights and will be immediately fungible with Kalray’s existing shares.

This Reserved Share Capital Increase is not subject to a prospectus requiring a visa from the AMF (Autorité des marchés financiers , the French financial market authority).

Lock-up commitment

In the context of the Reserved Share Capital Increase, NXP BV signed a 12-month lock-up commitment with respect to the New Shares taking effect on the date of their settlement-delivery, subject to certain customary exceptions.

Advisors in connection with the transaction

Advisors to Kalray

  • Legal counsel : Jones Day
  • Financial advisor: Rothschild & Co
  • Communication advisor: ACTUS finance & communication

Advisor to NXP

  • Legal counsel : Hogan Lovells

COVID-19 AND RISK FACTORS

Attention is drawn to the status shared by the Company, in another press release today, on the activity and continuation of its activity in the context of the Covid-19 epidemic and the various health measures taken by the government (cf: press release published today). Based on the information the company owns, Kalray confirms that its current cash position, including the NXP investment just announced, should allow the Company to develop its technology roadmap, including developments related to the NXP strategic partnership, as well as the commercial deployment, beyond the next twelve months. The Company will comment its 2019 results on April 20 as previously announced. By this timeframe, Kalray hopes to be in a position to provide more details on the impact of Covid-19 epidemic crisis on its business.

Attention is drawn as well to the risk factors associated with the Company and its activity presented in the Company’s annual report which is available free of charge on the Company’s website (www.kalray-bourse.com ). The occurrence of all or part of these risks could have a negative impact on the Company’s activity, financial situation, results, development or outlook. Subject to what is mentioned in this press release, and in particular the uncertainties related to the Covid-19 epidemic, the risk factors presented in that document are the same today.

Additionally, investors are invited to consider the following risks specific to this Reserved Share Capital Increase: (i) the market price of the Company’s shares may fluctuate and fall below the subscription price of the shares issued within the framework of the Reserved Share Capital Increase, (ii) the volatility and liquidity of the Company’s shares may fluctuate significantly, (iii) divestments of the Company’s shares may take place on the market and have a negative effect on its share price, (iv) the Company’s shareholders could suffer potentially significant dilution resulting from any future capital increases required to provide the Company with additional financing, and (v) as these shares are not intended to be listed on a regulated market, investors will not benefit from the guarantees associated with regulated markets.

Next publication:

Monday April 20, 2020 (after market close) : 2019 annual results

ABOUT NXP SEMICONDUCTORS

NXP Semiconductors N.V. (NASDAQ: NXPI) enables secure connections for a smarter world, advancing solutions that make lives easier, better, and safer. As the world leader in secure connectivity solutions for embedded applications, NXP is driving innovation in the automotive, industrial & IoT, mobile, and communication infrastructure markets. Built on more than 60 years of combined experience and expertise, the company has approximately 30,000 employees in more than 30 countries and posted revenue of $8.88 billion in 2019. Find out more at www.nxp.com .

ABOUT KALRAY

Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is the pioneer in processors for new intelligent systems. A genuine technological breakthrough, “intelligent” processors are able to intelligently analyze a vast quantity of data on the fly and to make decisions and interact in real time with the outside world. These intelligent processors will be largely deployed in fast-growing sectors such as new-generation networks (intelligent data centers) and autonomous vehicles, as well as in healthcare equipment, drones and robots. Kalray’s offering spans both processors and global solutions (electronic boards and software). Created in 2008 as a spin-off of CEA (“Commissariat à l’Énergie Atomique”, the French Alternative Energies and Atomic Energy Commission), Kalray addresses a broad spectrum of customers including server manufacturers, intelligent system integrators and consumer product manufacturers such as car makers. Read more at: www.kalrayinc.com

DISCLAIMER

With respect to Member States of the European Union, no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State. Therefore, such securities may not be and shall not be offered in any Member State other than in accordance with the exemptions of Article 1(4) of the regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”) or, otherwise, in cases not requiring the publication of a prospectus under Article 3 of the Prospectus Regulation and/or the applicable regulations in such Member State.

This press release and the information it contains are being distributed to and are only intended for persons who are (x) outside the United Kingdom or (y) in the United Kingdom and are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) high net worth entities and other such persons falling within Article 49(2)(a) to (d) of the Order (“high net worth companies”, “unincorporated associations”, etc.) or (iii) other persons to whom an invitation or inducement to participate in investment activity (within the meaning of Section 21 of the Financial Services and Market Act 2000) may otherwise lawfully be communicated or caused to be communicated (all such persons in (y)(i), (y)(ii) and (y)(iii) together being referred to as “Relevant Persons”). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities to which this press release relates will only be engaged with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this press release or any of its contents.

This press release and the information it contains do not, and will not, constitute a public offering nor an invitation to solicit the interest of public in France, nor an offer to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, securities of Kalray in the United States of America or any other jurisdiction where restrictions may apply. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), it being specified that the securities of Kalray have not been and will not be registered within the U.S. Securities Act. Kalray does not intend to register securities or conduct a public offering in the United States of America.

The distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions.

Any decision to subscribe for or purchase the shares or other securities of Kalray must be made solely based on information publicly available about Kalray.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye